NASDAQ
Esperion Therapeutics, Inc. (ESPR) has a revenue compound annual growth rate of 12.12% over 5 years and -22.22% over 10 years. Revenue CAGR shows the compound annual growth rate of a company's total sales, indicating the pace of top-line expansion.
No price data available for this timeframe.